The FDA is apparently considering loosening the conflict-of-interest rules that apply to members of FDA advisory committee members. These rules have set limits on the financial arrangements that members can have with companies in the health care industry.
The Project on Government Oversight wrote about the issue last week.
If the perceived problem is that the FDA can’t find enough non-conflicted experts to serve on the committee, we wonder if they’re looking hard enough.
Here’s a letter sent to the FDA commissioner today by Shannon Brownlee, Jeanne Lenzer and me:
And here is Shannon Brownlee’s blog post on the topic, “Is There An Independent, Unbiased Expert in the House?”